The intracellular expression of IFNγ in either CD4+ (Supplemental Figure S3A) or CD8+ T cells (Supplemental Figure S3B) remains unchanged between shScr-ST and shIDO-ST-treated groups, which may explain the lack of tumor control by sub-therapeutic doses of shIDO-ST alone (Figure 2B). This evidence concerns the gene CD8A and neoplasm.